CardioTech is a developer of advanced polymer materials and manufacturer
of medical products for the treatment and diagnosis of a broad range of
The Company's business model leverages its proprietary materials science
technology and manufacturing expertise in order to expand its product sales
and royalty and development fee income.
It develops next generation polymers and manufactures new and complex
medical devices to customers' unique specifications.
CardioTech is conducting its first clinical trial for regulatory approval
in Europe for its CardioPass synthetic coronary bypass graft (2008).